LAKE FOREST, Ill., April 1, 2011 /PRNewswire/ -- Hospira
(NYSE:HSP), a leading provider of clinical information and
medication delivery technologies, today announced the launch of its
enhanced TheraDoc™ clinical surveillance system, used by hospitals
to help improve patient safety and prevent adverse events such as
healthcare-associated infections (HAIs). The enhanced TheraDoc
system includes new features and functionalities designed to
improve user satisfaction, reporting capabilities and work
efficiency.
(Logo: http://photos.prnewswire.com/prnh/20040503/HSPLOGO)
Patient safety issues such as HAIs, adverse drug events and
antimicrobial resistant infections have been linked to increased
morbidity and mortality, and have an enormous financial impact on
healthcare institutions and society. An estimated 1.7 million
patients develop an HAI in the United
States each year, and 99,000 die as a result, adding $28–$33
billion in healthcare costs.(1)
The TheraDoc platform enhancements are designed to help
hospitals meet and improve upon evolving quality metrics and
national patient safety goals. The new platform also helps
clinicians more easily identify antimicrobial resistant pathogens
and drug-bug mismatches. Improvements to the TheraDoc Infection
Control Assistant™ module facilitate seamless electronic reporting
of HAIs to the National Healthcare Safety Network (NHSN) and
provide a new infection control dashboard for enhanced reporting,
data comparison and benchmarking. Clinicians and healthcare
institutions can now use TheraDoc to automatically track and
generate electronic reports regarding urinary tract infections
(UTI), central line insertion practices (CLIP),
laboratory-identified multi-drug resistant organisms (MDRO) and C.
difficile-associated disease (CDAD) events. This additional
functionality will help to decrease manual sorting of laboratory
results and streamline public health reporting.
"The enhanced TheraDoc platform has added even more valuable
tools available to our infection prevention team at Kootenai
Health," said Lee Rieken R.N.,
C.I.C., infection prevention unit supervisor, Kootenai Health in
Idaho. "The TheraDoc team
continues to reach out to its customers and listen to their needs.
As increasing demands are placed on the infection preventionist,
the tools afforded them are increasing as well. I appreciate the
dashboard within the new TheraDoc platform, because it is quite
intuitive to use and helps us benchmark against NHSN."
Stanley Pestotnik, M.S., R.Ph.,
general manager, TheraDoc, Hospira, said, "The enhanced TheraDoc
system reflects Hospira's commitment to delivering innovative
patient safety surveillance and clinical-decision support
solutions."
"TheraDoc systems are actively used in more than 300 U.S.
hospitals, making critical patient information and medical
knowledge readily available to help clinicians intervene quickly,
prescribe appropriately and improve the quality of patient care,"
Pestotnik said. "The enhancements to our platform will further
maximize these important benefits."
The TheraDoc clinical surveillance platform is being
demonstrated at Society for Healthcare Epidemiology of America
(SHEA) booth #107 through April 4.
For more information about TheraDoc, visit http://www.theradoc.com
or call (801) 415-4400.
About Hospira
Hospira, Inc., is a global specialty pharmaceutical and
medication delivery company dedicated to Advancing Wellness™.
As the world leader in specialty generic injectable
pharmaceuticals, Hospira offers one of the broadest portfolios of
generic acute-care and oncology injectables, as well as integrated
infusion therapy and medication management solutions. Through its
products, Hospira helps improve the safety, cost, and productivity
of patient care. The company is headquartered in Lake Forest, Ill., and has approximately
14,000 employees. Learn more at http://www.hospira.com.
Private Securities Litigation Reform Act of 1995 --
A Caution Concerning Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, including statements regarding the enhanced TheraDoc system.
Hospira cautions that these forward-looking statements are subject
to risks and uncertainties that may cause actual results to differ
materially from those indicated in the forward-looking statements.
Economic, competitive, governmental, regulatory, legal,
technological and other factors that may affect Hospira's
operations and may cause actual results to be materially different
from expectations include the risks, uncertainties and factors
discussed under the headings "Risk Factors" and "Management's
Discussion and Analysis of Financial Condition and Results of
Operations" in Hospira's latest Annual Report on Form 10-K filed
with the Securities and Exchange Commission, which are incorporated
by reference. Hospira undertakes no obligation to release publicly
any revisions to forward-looking statements as the result of
subsequent events or developments.
(1) U.S. Department of Health & Human Services. (n.d.)
Healthcare-Associated Infections,
http://www.hhs.gov/ash/initiatives/hai/ Accessed March 29, 2011
SOURCE Hospira